よむ、つかう、まなぶ。
03 資料１－１ 帯状疱疹ワクチンファクトシート (79 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_40826.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第26回 6／20）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
210.
Koh JH, Lee J, Kim SH, Kwok SK, Ju JH, Park SH. Safety, and Humoral and Cell-mediated Immune Responses
to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis. J Rheumatol 2018; 45(4): 465-9.
211.
Winthrop KL, Wouters AG, Choy EH, et al. The Safety and Immunogenicity of Live Zoster Vaccination in Patients
With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol 2017;
69(10): 1969-77.
212.
Calabrese LH, Abud-Mendoza C, Lindsey SM, et al. Live Zoster Vaccine in Patients With Rheumatoid Arthritis
Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of
Data From a Phase IIIb/IV Randomized Study. Arthritis Care Res (Hoboken) 2020; 72(3): 353-9.
213.
Mok CC. Herpes zoster vaccination in systemic lupus erythematosus: the current status. Hum Vaccin Immunother
2019; 15(1): 45-8.
214.
Benson CA, Andersen JW, Macatangay BJC, et al. Safety and Immunogenicity of Zoster Vaccine Live in Human
Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on
Antiretroviral Therapy. Clin Infect Dis 2018; 67(11): 1712-9.
215.
Hamad MA, Allam H, Sulaiman A, Murali K, Cheikh Hassan HI. Systematic Review and Meta-analysis of Herpes
Zoster Vaccine in Patients With CKD. Kidney Int Rep 2021; 6(5): 1254-64.
216.
Vermeulen JN, Lange JM, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster
vaccine in healthy adults ≥60 years of age. Vaccine 2012; 30(5): 904-10.
217.
Vesikari T, Hardt R, Rümke HC, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster)
vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose
schedules. Hum Vaccin Immunother 2013; 9(4): 858-64.
218.
Diez-Domingo J, Weinke T, Garcia de Lomas J, et al. Comparison of intramuscular and subcutaneous
administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority
clinical trial. Vaccine 2015; 33(6): 789-95.
219.
Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of
ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007; 55(10): 1499507.
220.
Levin MJ, Buchwald UK, Gardner J, et al. Immunogenicity and safety of zoster vaccine live administered with
quadrivalent influenza virus vaccine. Vaccine 2018; 36(1): 179-85.
221.
MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines
in adults ≥60 years old. Hum Vaccin 2010; 6(11): 894-902.
222.
Boutry C, Hastie A, Diez-Domingo J, et al. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term
Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE50 and ZOE-70. Clin Infect Dis 2022; 74(8): 1459-67.
223.
Hesse EM, Shimabukuro TT, Su JR, et al. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine
(Shingrix) - United States, October 2017-June 2018. MMWR Morb Mortal Wkly Rep 2019; 68(4): 91-4.
224.
Goud R, Lufkin B, Duffy J, et al. Risk of Guillain-Barre Syndrome Following Recombinant Zoster Vaccine in
Medicare Beneficiaries. JAMA Intern Med 2021; 181(12): 1623-30.
225.
Nelson JC, Ulloa-Perez E, Yu O, et al. Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine
78
Koh JH, Lee J, Kim SH, Kwok SK, Ju JH, Park SH. Safety, and Humoral and Cell-mediated Immune Responses
to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis. J Rheumatol 2018; 45(4): 465-9.
211.
Winthrop KL, Wouters AG, Choy EH, et al. The Safety and Immunogenicity of Live Zoster Vaccination in Patients
With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol 2017;
69(10): 1969-77.
212.
Calabrese LH, Abud-Mendoza C, Lindsey SM, et al. Live Zoster Vaccine in Patients With Rheumatoid Arthritis
Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of
Data From a Phase IIIb/IV Randomized Study. Arthritis Care Res (Hoboken) 2020; 72(3): 353-9.
213.
Mok CC. Herpes zoster vaccination in systemic lupus erythematosus: the current status. Hum Vaccin Immunother
2019; 15(1): 45-8.
214.
Benson CA, Andersen JW, Macatangay BJC, et al. Safety and Immunogenicity of Zoster Vaccine Live in Human
Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on
Antiretroviral Therapy. Clin Infect Dis 2018; 67(11): 1712-9.
215.
Hamad MA, Allam H, Sulaiman A, Murali K, Cheikh Hassan HI. Systematic Review and Meta-analysis of Herpes
Zoster Vaccine in Patients With CKD. Kidney Int Rep 2021; 6(5): 1254-64.
216.
Vermeulen JN, Lange JM, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster
vaccine in healthy adults ≥60 years of age. Vaccine 2012; 30(5): 904-10.
217.
Vesikari T, Hardt R, Rümke HC, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster)
vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose
schedules. Hum Vaccin Immunother 2013; 9(4): 858-64.
218.
Diez-Domingo J, Weinke T, Garcia de Lomas J, et al. Comparison of intramuscular and subcutaneous
administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority
clinical trial. Vaccine 2015; 33(6): 789-95.
219.
Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of
ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007; 55(10): 1499507.
220.
Levin MJ, Buchwald UK, Gardner J, et al. Immunogenicity and safety of zoster vaccine live administered with
quadrivalent influenza virus vaccine. Vaccine 2018; 36(1): 179-85.
221.
MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines
in adults ≥60 years old. Hum Vaccin 2010; 6(11): 894-902.
222.
Boutry C, Hastie A, Diez-Domingo J, et al. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term
Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE50 and ZOE-70. Clin Infect Dis 2022; 74(8): 1459-67.
223.
Hesse EM, Shimabukuro TT, Su JR, et al. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine
(Shingrix) - United States, October 2017-June 2018. MMWR Morb Mortal Wkly Rep 2019; 68(4): 91-4.
224.
Goud R, Lufkin B, Duffy J, et al. Risk of Guillain-Barre Syndrome Following Recombinant Zoster Vaccine in
Medicare Beneficiaries. JAMA Intern Med 2021; 181(12): 1623-30.
225.
Nelson JC, Ulloa-Perez E, Yu O, et al. Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine
78